NASDAQ
3.41USD
+0.05 (+1.49%)
We have scored 11 news catalysts on Opthea Limited (OPT) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.81). Most of the impact sits in forward growth expectations and revenue growth rate.
Market cap
4.2B
P/E
—
EPS
—
Beta
1.67
52W range
—
Day range
3.41–3.41
Open
3.41
Prev close
3.36
Volume
3K
Avg volume
32.3K
Dividend
0.00
IPO
2020-10-16
No scored news tagged OPT or its network in the window yet.
Show more OPT articles →Opthea Limited is an Australian biopharmaceutical company operating at the clinical development stage, focused on discovering and commercializing treatments primarily for ophthalmic conditions. Its research and development efforts are underpinned by an intellectual property portfolio that covers Vascular Endothelial Growth Factors (VEGF) C and D, along with VEGF Receptor-3. This proprietary foundation targets diseases stemming from abnormal blood and lymphatic vessel growth or vascular leakage. The company's primary therapeutic candidate, OPT 302, is a soluble form of VEGFR-3 currently undergoing clinical evaluation. This novel agent is being developed for treating wet neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Furthermore, OPT 302 is designated as a pioneering VEGF C/D inhibitor, designed for administration alongside VEGF A inhibitors to manage wet neovascular AMD and other retinal diseases. Founded in 1984, the company officially changed its name from Circadian Technologies Limited to Opthea Limited in December 2015. Its corporate headquarters are located in South Yarra, Australia.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Opthea Limited — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for OPT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
